

DarioHealth Corp. (DRIO)

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001533998

DarioHealth Corp.
DRIO; healthcare

Grade	E A B C D E weakest fifth of 371 graded peers percentile 86.8; sampling error 2.5 points; lower is stronger
Rank	322 of 371
Profitability	D percentile 64.7
Solvency	C percentile 48.7
Growth and financing	D percentile 77.3
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$110.1M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	dilution, short runway not computable: distress, fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Mar 19, 2026 204 days before the rescans; latest periodic filing 10-Q received Aug 11, 2026
Last close	\$5.61 2026-10-08; market equity \$55.0M
Price used in grade	None



E, the bear
weakest fifth of its sector;
letters are fifths of the 371
graded peers

Share price, twelve months to the rescan
split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: B from Aug 21, 2024, B/C from Sep 21, 2024, B from Dec 21, 2024.

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 19, 2026

We are a vertically integrated health intelligence platform with a mission to power the behavior changes that drive better health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, AI built on that proprietary data, and a behavior change and coaching layer validated through over 100 peer-reviewed clinical studies. We are committed to transforming healthcare by

delivering a comprehensive and highly engaging whole-person health platform, which enables us to create a future where healthy change is effortless and accessible to all.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 64.7						
Gross profitability		11.5%	32.2%	74.1	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(13.8%)	(6.6%)	32.5	811	2025-12-31
Gross margin stability, five years		13.4 pts	2.8 pts	87.6	243	2025-12-31
Solvency, sleeve percentile 48.7						
Twelve-month failure probability		not computable	0.07%			liabilities and a nearby cover-page share count are required at 2026-06-30
Altman Z double-prime		not computable	(0.31)			one or more required annual facts are missing
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		3.76x	2.96x	48.7	839	2025-12-31
Growth and financing, sleeve percentile 77.3						
Revenue growth, three-year compound		(6.8%)	10.0%	82.6	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000 pretax income
Reinvestment rate		not computable	37.1%			must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		(2.6%)	2.1%	58.0	704	2025-12-31
Net share issuance, one year		251.4%	2.5%	91.2	634	2026-03-11


Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 251.4%

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
317	Organon & Co. (OGN)	85.4	E	
318	Sonoma Pharmaceuticals, Inc. (SNOA)	85.7	E	dilution, fortress balance sheet
319	Outset Medical, Inc. (OM)	85.9	E	dilution
320	National Vision Holdings, Inc. (EYE)	86.2	E	
321	Natural Alternatives International Inc. (NAII)	86.5	E	dilution, late filer, fortress balance sheet
322	DarioHealth Corp. (DRIO) <	86.8	E	dilution, short runway
323	Intellia Therapeutics, Inc. (NTLA)	87.0	E	short runway
324	Heron Therapeutics, Inc. (HRTX)	87.3	E	distress
325	Lexaria Bioscience Corp. (LEXX)	87.6	E	dilution, short runway, distress
326	Intelligent BIO Solutions Inc. (INBS)	87.8	E	dilution, short runway
327	Bristol Myers Squibb Co. (BMY)	88.2	E	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(57.5%)	8.0%	11
Distance from 52-week high	(66.8%)	(31.4%)	13
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(49.0%)	(1.0%)	12
Book value to price	1.04	0.28	86
Sales to price	0.42	0.31	61
Composite equity issuance, five years	255.2%	20.3%	93
Relative strength against the sector, log excess return	(1.07)	(0.14)	11

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 4 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass

Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$6.6M
Operating cash flow, four quarters	-\$25.3M
Months of runway	3.1
Days since last periodic filing	59 (10-Q received Aug 11, 2026)
Median daily dollar volume, 63 sessions	\$85,584

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$12.7M	2025-12-31	2026-03-19	10-K	0001104659-26-031621
2	assets	us-gaap:Assets	\$110.1M	2025-12-31	2026-03-19	10-K	0001104659-26-031621
3	net income	us-gaap:NetIncomeLoss	-\$41.7M	2025-12-31	2026-03-19	10-K	0001104659-26-031621
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$25.9M	2025-12-31	2026-03-19	10-K	0001104659-26-031621
5	assets	us-gaap:Assets	\$118.9M	2024-12-31	2026-03-19	10-K	0001104659-26-031621
6	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$22.4M	2025-12-31	2026-03-19	10-K	0001104659-26-031621
7	gross profit	us-gaap:GrossProfit	\$13.3M	2024-12-31	2026-03-19	10-K	0001104659-26-031621
8	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$27.0M	2024-12-31	2026-03-19	10-K	0001104659-26-031621
9	gross profit	us-gaap:GrossProfit	\$6.0M	2023-12-31	2025-03-10	10-K	0001558370-25-002527
10	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$20.4M	2023-12-31	2025-03-10	10-K	0001558370-25-002527
11	gross profit	us-gaap:GrossProfit	\$9.7M	2022-12-31	2024-03-28	10-K	0001558370-24-004151
12	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$27.7M	2022-12-31	2024-03-28	10-K	0001558370-24-004151
13	gross profit	us-gaap:GrossProfit	\$4.0M	2021-12-31	2023-03-09	10-K	0001558370-23-003240
14	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$20.5M	2021-12-31	2023-03-09	10-K	0001558370-23-003240
15	current assets	us-gaap:AssetsCurrent	\$35.1M	2025-12-31	2026-03-19	10-K	0001104659-26-031621
16	current liabilities	us-gaap:LiabilitiesCurrent	\$9.3M	2025-12-31	2026-03-19	10-K	0001104659-26-031621
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$142,000	2025-12-31	2026-03-19	10-K	0001104659-26-031621
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$38.6M	2024-12-31	2026-03-19	10-K	0001104659-26-031621
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$138,000	2024-12-31	2026-03-19	10-K	0001104659-26-031621
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$30.4M	2023-12-31	2025-03-10	10-K	0001558370-25-002527
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$584,000	2023-12-31	2025-03-10	10-K	0001558370-25-002527
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$47.8M	2022-12-31	2024-03-28	10-K	0001558370-24-004151
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$442,000	2022-12-31	2024-03-28	10-K	0001558370-24-004151
24	depreciation amortization	us-gaap:Depreciation	\$307,000	2025-12-31	2026-03-19	10-K	0001104659-26-031621
25	operating income	us-gaap:OperatingIncomeLoss	-\$36.7M	2025-12-31	2026-03-19	10-K	0001104659-26-031621
26	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$11.6M	2025-12-31	2026-03-19	10-K	0001104659-26-031621
27	income tax	us-gaap:IncomeTaxExpenseBenefit	\$105,000	2025-12-31	2026-03-19	10-K	0001104659-26-031621
28	current assets	us-gaap:AssetsCurrent	\$40.5M	2024-12-31	2026-03-19	10-K	0001104659-26-031621
29	current liabilities	us-gaap:LiabilitiesCurrent	\$16.6M	2024-12-31	2026-03-19	10-K	0001104659-26-031621
30	assets	us-gaap:Assets	\$96.4M	2023-12-31	2025-03-10	10-K	0001558370-25-002527
31	assets	us-gaap:Assets	\$119.2M	2022-12-31	2024-03-28	10-K	0001558370-24-004151
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	7,300,406	2026-03-11	2026-03-19	10-K	0001104659-26-031621
33	shares outstanding	dei:EntityCommonStockSharesOutstanding	41,567,016	2025-03-03	2025-03-10	10-K	0001558370-25-002527